Feasibility of Neuromodulation With Connectivity-Guided iTBS for Cognitive Impairment in MS
NCT04931953 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2023-06-12
Summary
Cognitive difficulties can affect many people who live with multiple sclerosis (MS). These difficulties, such as within thinking, memory, and problem solving, can have an impact on important aspects of an individual's life, including their daily activities, work, and how they manage their condition. Previous studies have suggested that cognitive difficulties affect approximately 40-70% of people living with MS, yet there are currently no treatments to target these problems. Recent research has directed towards a non-invasive intervention which stimulates a part of the brain (called the dorsolateral prefrontal cortex, or DLPFC for short) which is reported to participate in cognitive processes, such as memory, thinking, and attention. This intervention, called "intermittent theta burst stimulation" (iTBS), involves placing a magnetic device to the skull to activate the DLPFC underneath. This technique has been used successfully in the treatment of depression and is widely considered safe and painless. Previous studies have also shown that iTBS intervention can lead to improvements in cognitive processes.
Before the investigators can progress to a large trial to explore its clinical effectiveness for reducing cognitive problems for people with MS, some aspects regarding its feasibility need to be clarified, for example whether it is an acceptable and tolerable intervention for people living with MS. A single-centre, mixed methods feasibility randomised controlled trial will be conducted to compare four groups (10 participants each) of iTBS administration. At baseline, End of Intervention (EOI), and 8-week follow up, the investigators will complete outcome measures to evaluate cognition, mood and fatigue. Participants will also undergo MRI scans at baseline and EOI. Following participation, participants will be interviews and the investigators will organise a post-participation workshop to explore their experiences of the trial, including the tolerability of the protocol and acceptability of the visit schedule, and any differences in cognition.
Conditions
Interventions
- OTHER
-
Intermittent theta burst stimulation (iTBS)
The localisation of the left dorsolateral prefrontal cortex (DLPFC) target will be identified using effective connectivity of the left caudate to identify the maximally-connected locus in the left DLFPC. Following this the iTBS will be administered to the target coordinates identified using the neuronavigation software available with the system. Connectivity-guided iTBS is then administered using a 70mm Double Air Film Coil (Magstim, Whitland, Dyfed, UK), connected to a Magstim Super Rapid-2 Plus-1 stimulator. The administration comprises bursts of 3 pulses at 50Hz with a power of 80% motor threshold at a burst frequency of 5 Hz (i.e., every 200ms) for 2 seconds, repeated every 10 seconds for a total of 190 seconds (600 pulses). Blocks are repeated a total of 3 times, with 5-minute rest intervals between blocks. During left DLPFC stimulation, the TBS coil is held by a support tangentially to the skull, with the axis of the coil angled approximately 90 degrees from the midsagittal axis.
- OTHER
-
Sham Intermittent theta burst stimulation (iTBS)
The sham iTBS administration is performed under the same conditions and with an identical protocol and equipment to the full administration, except that it uses a commercially available sham iTBS coil designed for use in double-blind trials. This sham coil looks like the real coil and connects to the iTBS unit but delivers only a very weak and shallow stimulation thus simulating the sounds made by the real iTBS coil.
Sponsors & Collaborators
-
University of Nottingham
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 69 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-01
- Primary Completion
- 2023-08-31
- Completion
- 2023-12-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial
NCT04975685 ·Status: RECRUITING ·Phase: NA
-
Electrical Brain Stimulation for Treatment of Secondary Symptoms in Multiple Sclerosis
NCT06401928 ·Status: COMPLETED ·Phase: NA
-
Identifying and Managing Psychological Distress in Multiple Sclerosis: The COMPASS-MS Study
NCT06222359 ·Status: NOT_YET_RECRUITING
-
Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting
NCT03047460 ·Status: COMPLETED
-
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
NCT01719159 ·Status: COMPLETED ·Phase: PHASE2
-
A RCT of Telephone-supported ACT in MS
NCT02596633 ·Status: UNKNOWN ·Phase: PHASE3
-
Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)
NCT02301247 ·Status: COMPLETED ·Phase: NA
-
Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients
NCT02623946 ·Status: COMPLETED
-
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
NCT00333138 ·Status: COMPLETED ·Phase: PHASE2
-
Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)
NCT01419301 ·Status: COMPLETED ·Phase: NA
-
Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis
NCT06283524 ·Status: COMPLETED
-
Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
NCT00300716 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Online Program to Reduce Depression in MS
NCT02740361 ·Status: COMPLETED ·Phase: NA
-
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00917839 ·Status: UNKNOWN ·Phase: PHASE2
-
Development of a Motivational Intervention to Improve Treatment Adherence in MS
NCT01925690 ·Status: COMPLETED ·Phase: NA
-
Remediation of Emotional Processing Deficits in MS
NCT03373344 ·Status: COMPLETED ·Phase: NA
-
Meeting an Unmet Need in Multiple Sclerosis
NCT05953519 ·Status: RECRUITING ·Phase: NA
-
Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
NCT00342134 ·Status: COMPLETED ·Phase: PHASE2
-
Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target
NCT03850301 ·Status: RECRUITING ·Phase: NA
-
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression
NCT05941975 ·Status: RECRUITING ·Phase: NA
-
Screening for Cognitive Disorders in Multiple Sclerosis
NCT07030036 ·Status: NOT_YET_RECRUITING
-
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
NCT01517282 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis
NCT01142583 ·Status: COMPLETED
-
Self Help for Fatigue in Multiple Sclerosis
NCT01532037 ·Status: COMPLETED ·Phase: NA
-
Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant
NCT01392872 ·Status: COMPLETED ·Phase: NA